What do adults die in Mexico? Impact on the economic and social development of the nation. The global burden of cardiovascular disease
Main Article Content
Keywords
Cardiovascular diseases, Heart diseases, Risk factors, Mexico
Abstract
Noncommunicable diseases have been established as a clear threat, not only to human health but also to the development and economic growth. Claiming 63% of all deaths, these diseases are currently the main murderer worldwide. The increase in the prevalence and importance of noncommunicable diseases specifically of cardiovascular risk factors such as hypertension, diabetes, dyslipidemia and obesity is the result of a complex interplay between health, economic growth and development, which is strongly associated with universal trends such as the aging of the world population, rapid unplanned urbanization, and the globalization of unhealthy lifestyles.Cardiovascular disease refers to a group of diseases involving the heart, blood vessels, or the consequences of poor blood supply due to a vascular source ill. About 82% of the burden of mortality is caused by ischemic heart disease or coronary heart disease (IHD), Stroke (both hemorrhagic and ischemic), hypertensive heart disease or congestive heart failure (CHF). The Hospital de Cardiología of the Centro Médico Nacional Siglo XXI, serves the call to improve through innovation and technological development this area of health the “tele cardiology” (regulatory center of myocardial code), with clear objectives in the short, medium and long term.
References
Navarro V, Shi L. The Political Context of Social Inequalities and Health. Soc Sci Med. 2001;53(3):481-491.
Schwartz ID. “Globesity” and units of measurements. J Pediatr. 2005;146(4):577.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480-486.
Secretaría de Gobenación. Plan Nacional de Desarrollo 2013-2018. Distrito Federal, México: Diario Oficial de la Federación; 2013.
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence and future trends. Lancet. 2007;370(9589):765-773.
Nielsen R, Johannessen A, Benediktsdottir B, Gislason T, Buist AS, Gulsvik A et al. Present and future costs of COPD in Iceland and Norway: results from the BOLD study. Eur Respir J. 2009;34(4):850-857.
Parry CD, Rehm J. Addressing harmful use of alcohol is essential to realizing the goals of the UN resolution on non-communicable diseases (NCDs): Global Alcohol Policy Alliance, 2011.
Rehm J, Baliunas D, Borges GLG, Graham K, Irving H, Kehoe T et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction. 2010;105:817-843.
Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
Woolf, S. H. (2009). A closer look at the economic argument for disease prevention. JAMA, 2009;301(5), 536-538.
Braveman PA, Egerter S, Chideya S, Marchi KS, Metzler M, Posner S. Socioeconomic status in health research: one size does not fit all. JAMA. 2005;294(22):2879-2888.
Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries: a review. Bull World Health Organ. 2004;82(12):940-946.
Bloom DE, Cafiero ET, Jané-Llopis E, Abrahams-Gessel S, Bloom LR, Fathima S et al. The Global Economic Burden of Noncommunicable Diseases. Geneva: World Economic Forum. 2011.
Abegunde D, Mathers D, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370(9603):1929-1938.
Brownell KD, Frieden TR. Ounces of prevention-the public policy case for taxes on sugared beverages. N Engl J Med. 2009;360(18):1805-1808.
Bifulco M, Caruso MG. From the gastronomic revolution to the new globesity epidemic. J Am Diet Assoc. 2007;107(12):2058-2060.
Anderson G, Horvath J. The growing burden of chronic disease in America. Public Health Rep. 2004;119(3):263-270.
Schuftan C. Equity in health and economic globalisation. Dev Pract. 1999;9(5):610-614.
American Cancer Society, World Lung Foundation. (2011). Tobacco Atlas. Anderson G, & Horvath J. (2002). Chronic Conditions: Making the Case for Ongoing Care. Princeton, NJ: Robert Wood Johnson Foundation’s Partnership for Solutions.
Cecchini M, Sassi F, Lauer JA, Lee YY, Guajardo-Barron V, Chisholm D. Tackling of unhealthy diets, physical inactivity, and obesity: health effects and cost-effectiveness. Lancet. 2010;376(9754):1775-1784.
Deitel M. The International Obesity Task Force and “globesity”. Obes Surg. 2002;12(5):613-614.
Ezzati M, Vander Hoorn S, Lawes C, Leach R, James W, Lopez AD et al. Rethinking the “Diseases of the Affluence” Paradigm: Global Patterns of Nutritional Risk in Relation to Economic Development. PLoS Medicine. 2005;2(5):e133.
Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A. Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries. Current problems in cardiology. 2010;35(2):72-115.
Beckfield J, Krieger N. Epi+Demos+Cracy: Linking political systems and priorities to the magnitude of health inequalities - evidence, gaps and a research agenda. Epidemiol Rev. 2009;31(1):152-177.
Johansson PO. Is there a meaningful definition of the value of a statistical life? J Health Econ. 2001;20(1):131-139.
Mayer-Foulkes D. A survey of macro damages from non-communicable chronic diseases: Another challenge for global governance. Global Economy Journal. 2011;11(1).123-28.
McLaren L. Socioeconomic status and obesity. Epidemiol Rev. 2007;29:29-48.
Global Tobacco Surveillance System. Global Adult Tobacco Survey - China Section (2010). Disponible en: http://global.tobaccofreekids.org/files/pdfs/en/GATS_china_2010.pdf.
Boffetta P, Hashibe M. Alcohol and Cancer. Lancet Oncol. 2006;7:149-156.
Gaziano TA, Bitton A, Anand S, Weinstein MC, International Society of Hypertension. The global cost of nonoptimal blood pressure. Journal of Hypertension. 2009;27(7):1472-1477.
Halbert RJ, Isonaka S, George D, Iqbal A. Interpreting COPD prevalence estimates: What is the true burden of disease? Chest. 2003;123(5):1684-1692.
Suhrcke M, Nugent RA, Stuckler D, Rocco L. Chronic Disease: An Economic Perspective. Oxford, UK: Oxford Health Alliance, 2006.